Navigation Links
Cytopia Merger with Toronto-based YM BioSciences Inc.
Date:10/5/2009

and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter a Phase 1/II clinical study in 2009.

About YM

YM BioSciences Inc. is a life sciences product development company that identifies and advances a portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF®, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

About YM Programs

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in more than 20 countries. In more than 5,000 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology.

YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities o
'/>"/>

SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
2. Cytopia Presentation on VDA CYT997 at AACR Conference
3. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
4. Cytopia Letter to Progen Shareholders
5. Cytopia and Other Progen Shareholders Maintain Call for Meeting
6. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
7. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
8. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
9. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
10. Schering-Plough Shareholders Approve Merger With Merck
11. TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... NEW YORK , June 1, 2015 /PRNewswire/ ... medical researcher  Eliseo Oreste Salinas , MD, MSc, ... and development. Dr. Salinas, who holds ... in pharmacology, brings a record of significant accomplishments ... in psychiatry.  Dr. Salinas has played ...
(Date:6/1/2015)... , June 1, 2015 ... Decipher® genomic analysis platform, successfully classified various ... genomic expression of certain biomarkers, including one ... Importantly, this unique genomic signature has potential ... to neoadjuvant chemotherapy in patients with muscle-invasive ...
(Date:6/1/2015)... , June 1, 2015 ... the addition of the "Global PDT Machine ...        (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... 2014 is a professional and in-depth study on ... ,The report provides a basic overview of the ...
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, ... of positive interim results from a poster presented ... open label randomised phase III trial of the ... in patients receiving cisplatin (Cis) monotherapy for standard ... the American Society of Clinical Oncology (ASCO) 2015 ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Global PDT Machine Industry Report 2014 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4
... and more powerful ways to encrypt sensitive information. But ... is an extremely delicate business. Now two physicists have ... in quantum communication, while keeping the information intact. Their ... Physical Review Letters and highlighted with a Viewpoint ...
... Neogen Corporation (Nasdaq: NEOG ) announced today that Richard ... at the company,s recent annual meeting of shareholders. , Crowder ... agriculture, and trade industries and currently serves as an adjunct ... 2006 until May 2007, he served as United States chief ...
... , MOUNTAIN ... Growth Partnership Company, honored healthcare companies for demonstrating leadership ... in Healthcare Innovation Awards Banquet held in San Antonio, ... Healthcare Innovation Awards are given to companies that have ...
Cached Biology Technology:Richard T. Crowder Joins Neogen's Board of Directors 2Excellence in Healthcare Innovation Recognized by Frost & Sullivan 2Excellence in Healthcare Innovation Recognized by Frost & Sullivan 3
(Date:5/26/2015)... Research and Markets ( ... "Saudi Arabia Biometric Systems Market Forecast and ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... to grow at over 22% CAGR through 2020 ... the surging demand for better biometric technologies in ...
(Date:5/22/2015)... According to a new market ... Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, ... and Home) - Global Forecast to 2020", published by ... in 2015 to $6.19 Billion by 2020, at a ... data Tables and   43 Figures spread through 140 ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... OTTAWA November 14, 2010 One of the largest, ... University of Ottawa Heart Institute (UOHI), conclusively proves that a ... while reducing risk of death by 24% compared to the ... and Dr. George Wells at the Heart Institute, brings the ...
... Kritzer, assistant professor in the School of Arts and ... awarded one of 33 NIH Director,s New Innovator Awards, ... National Institutes of Health. The NIH Director,s New ... creative new investigators with highly innovative research ideas at ...
... the association for informatics professionals, honors four leaders ... 2010, with the annual presentation of its Signature ... Monday, Nov. 15 at the Opening Session of ... Informatics in Washington, D.C., before an audience of ...
Cached Biology News:Synchronizing a failing heart 2Tufts University chemist earns prestigious award for promising research on drug development 2Recognition given for ground-breaking advancements in digitalizing health data and information 2Recognition given for ground-breaking advancements in digitalizing health data and information 3Recognition given for ground-breaking advancements in digitalizing health data and information 4
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Biology Products: